Inbrx 106 Graphic

the Candidate

Our hexavalent OX40 agonist.

Hexavalent engagement of OX40 is designed to:

  • Provide co-stimulation to activated T-cells.
  • Reverse regulatory T-cell induced immune suppression.
  • Enhance T-cell functionality.

Going Beyond the Bivalent Approach

We believe that INBRX-106 can outperform bivalent agonists and has the potential to be widely used in combination with approved checkpoint inhibitors and also effective in tumors non-responsive to approved checkpoint inhibitors.

cd4 + T-cell Proliferation

Inbrx 106 Graphic 01

Comparison of Signaling

Inbrx 106 Graphic 02
Inhibrx Block 03

INBRX-106 Clinical Trial

Part 1, single agent dose escalation, of the Phase 1 trial for INBRX-106 was completed in January 2021. Parts 2 and 3, single agent dose expansion and dose escalation in combination with Keytruda, are currently enrolling in the following tumor types:

  • Solid Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Melanoma
  • Head and Neck Cancer (HNSCC)
  • Gastric (GIST) and Gastroesophageal Adenocarcinoma (GEA) Cancer
  • Renal Cell Carcinoma (RCC)
  • Urothelial (transitional) Carcinoma (TCC)
clinicaltrials.gov